The first PCR (Polymerase Chain Reaction) fully created with Cuban technology for Covid-19 diagnose and some other drugs could be registered by Cuba this year.

According to Gramma, Rolando Pérez Rodríguez, director of Sciences and Innovation of BioCubaFarma explained that the test in its last stage of development.

Rolando Pérez detailed that, from the favorable impacts observed, the country should conclude 2022 with the definite clearance for the use of the vaccines Abdala, Soberana 02 and Soberana Plus, and the likely sanitary registration of Soberana 01 and Mambisa, which would represent a significant outcome for the Cuban science when turning its five vaccine candidates against the Covid-19 into finished products, validated for its use.

Read: Anti-Covid vaccines are recognized by the World Organization of Intellectual Property.

Pérez added that BioCubaFarma is also working on 101 innovation projects, whose therapy areas of appliance are mainly focused on Oncology, Immunology and Neurology.

Read: Cuban drug against Alzheimer offers hope to the world.

https://lahabana.gob.cu/post_detalles/13247/farmaco-de-cuba-contra-el-alzheimer-esparanza-al-mundo

He pointed out that 20 products potentially stand out as the first of its kind, which mean, that they own a totally new mechanism which differs from the rest of the existent in the market.

15 of them are linked to cancer treatment (8) and brain diseases (7), which got the Cuban and international patent.

In the relation it is the molecule obtained by the chemical synthesis JM-20 to be used in the treatment of neurologic diseases. This product presents antioxidant, anti-inflammatory and ant calcic properties and the CIGB-845 peptide, also destined to neurologic diseases and whose clinical trial I and II in patients with brain ischemia concluded with encouraging outcomes.

The Savax project of activated immunotherapy, focused on the production of an innovative product with anti-angiogenic effects (lower the formation of blood vessels in the carcinoma, therefore, inhibiting its growth) conceived mostly for the treatment of solid tumors.

Right now, this drug is in its clinical trial phase II execution in ovaries cancer and hepatocellular carcinoma.

Created in 2012, BioCubaFarma products are being exported to more than 40 countries nowadays while the number of sanitary registrations rise to 740 in 53 nations.

During 2021 the number of paper published on researches in international magazines of impact was 228 and 45 of the outcomes were introduced, concluded Gramma.

Read: Cuban experts present standard reference chart for the human brain development.

https://lahabana,gob.cu/post_detalles/13416/expertos-cubanos-presentan-cuadros-de-referencia-estandarizados-para-el-desarrollo-del-cerebro-humano